On the 4th, Celltrion announced that it will introduce 'Steqeyma' and 'Omriclo' in Australia. Steqeyma is the autoimmune disease treatment drug Stelara (ingredient name ustekinumab), and Omriclo is the biosimilar of the allergy treatment drug Xolair.
The products will be sold by Celltrion's Australian subsidiary and local distribution partner Arotex. The company projects that, as Australia operates a biosimilar support system, it can accelerate market expansion.
Next year, there are plans to launch the bone disease treatment drug 'Stovolco Osentbelt' (ingredient name denosumab) and the autoimmune disease treatment drug 'Aptozma' (ingredient name tocilizumab) in the Oceania region. A Celltrion official noted, "We will establish a customized sales strategy considering the market environments of Australia and New Zealand."